Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%...

Related Keywords

Stockholm ,Sweden ,United States ,America ,Jonathan Graham ,Marlena Abdinoor ,Sloan Simpson ,Loreto Mda ,Parag Mahanti ,Lambers Heerspink ,Bartonm Endothelin ,Michael Meo ,Novartis Fabhalta ,Prnewswire Novartis ,European Renal Association ,Instagram ,Linkedin ,Fibrotic Transcriptional Networks ,Novartis Pharmaceuticals Corporation ,Exchange Commission ,Novartis ,Facebook ,Endpoint Analysis ,Atrasentan Shows Significant Reduction ,Iga Nephropathy ,Endothelin Receptor Typeb Expression ,Glomerular Diseases ,Receptor Immunoreactivity ,Endothelin Antagonists ,Chronic Kidney ,Improving Global Outcomes ,Practice Guideline ,Proteinuria Improves Prognosis ,Interim Results ,Kidney Int ,Surrogate End Point ,Clinj Am Soc ,Placebo Controlled Study ,Progressive Loss ,Renal Function ,Accessed May ,Long Term Safety ,Month Extension Study Data ,Patients Enrolled ,Primary Iga Nephropathy ,Interim Analysis Results ,Good Tolerability ,Basket Study ,Proteinuric Glomerular Diseases ,Receptor Blockade Reduces Diabetic Renal Injury ,Selective Endothelin ,Intra Renal Proliferative ,Rat Model ,Nephrol Dial ,Central Role ,Receptor Activation ,Mesangial Cell ,Podocyte Crosstalk ,Rapidly Reduces Albuminuria ,Downregulates Intra Renal Pro Inflammatory ,Pro Fibrotic Transcriptional Networks ,Spontaneous Iga ,Primary Glomerulonephritis Worldwide ,Systematic Review ,New Clinical Progression Risk ,New Novartis Fabhalta ,